Organs-on-chips could make difference in drug screening

Researchers, led by University of California, Irvine professor Christopher C.W. Hughes, have developed multiple vascularized organs on a 96-well plate. These tissues give researchers a look at how the flow of blood through the vascular system deliver nutrients to the entire body.

"This is truly a unique platform—we have recreated in a dish the key element common to all tissues, which is that they depend on blood vessels for their survival. This feature is missing in all previously described in vitro organ cultures," said Hughes.

Along with Duc T. T. Phan, first author on the study, Hughes and the team established a functional vascularized microtumor (VMT) with potential for anti-cancer drug screening. Along with a panel of FDA-approved anti-cancer drugs and a human colon cancer, researchers showed the accuracy of the VMT to identify drugs capable of targeting tumor cells and/or the vessels that supply them with blood.

"This is a major breakthrough," said Hughes. "For the first time we can identify in the same assay drugs that target both tumor cells and the vessels that feed them."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.